At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 19 enrolled
Drug / intervention
Bilastine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria
Menarini International Operations Luxembourg SA·interventional·Posted Oct 15, 2015·Updated Apr 18, 2017
In Brief
A Phase 4 clinical trial evaluating Bilastine and Placebo for Allergic Rhinitis and Urticaria. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The aim of the study is to evaluate the effects of Bilastine on patients' attention and reactivity levels by measuring psychophysical performance at a F1-high speed simulator driving test.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis, Urticaria
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedOct 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedOct 15, 2015
Enrollment StartOct 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.7 years ago
Interventions
Bilastinedrug
Bilastine tablets once a day for 7+3 days
Placebodrug
Placebo tablets once a day during 7+3 days run in period